Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$3.11
$3.22
$1.98
$3.60
$29.23M1.5222,722 shs12,261 shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$192.04
+0.5%
$175.50
$111.09
$199.99
$11.68B0.41564,039 shs383,694 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
NVV
Norvista Capital
C$0.08
-6.3%
C$0.08
C$0.07
C$0.23
C$5.26MN/A116,000 shs112,500 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
0.00%0.00%0.00%0.00%+26.94%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.50%+0.89%+9.89%+21.85%+37.52%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%0.00%0.00%
NVV
Norvista Capital
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.2262 of 5 stars
4.51.00.00.03.21.70.6
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
NVV
Norvista Capital
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$10.00221.54% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$242.9326.50% Upside
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00
N/AN/AN/A
NVV
Norvista Capital
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVV, ACST, NEPT, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$289.00 ➝ $295.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$243.00 ➝ $290.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$210.00 ➝ $230.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$306.00 ➝ $307.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$212.00 ➝ $220.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $203.00
8/8/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$212.00 ➝ $254.00
7/29/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$245.00 ➝ $254.00
7/11/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$213.00 ➝ $243.00
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$6.57 per shareN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M29.84N/AN/A($3.48) per share-55.18
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
NVV
Norvista Capital
-C$1.27M-4.13C$0.12 per share0.63C$0.11 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$5.16N/A800.17N/A-54.94%N/A-24.31%N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/A
NVV
Norvista Capital
N/A-C$0.05N/AN/AN/AN/AN/AN/A

Latest NVV, ACST, NEPT, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
NVV
Norvista Capital
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
7.86
7.86
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.02
0.69
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
NVV
Norvista Capital
0.07
11.62
11.58

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
14.44%
NVV
Norvista Capital
N/A

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
5.10%
NVV
Norvista Capital
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.77 millionNot Optionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.15 million36.69 millionOptionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
NVV
Norvista Capital
1,99070.14 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acasti Pharma stock logo

Acasti Pharma NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$192.04 +0.96 (+0.50%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$192.04 0.00 (0.00%)
As of 08/14/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Neptune Wellness Solutions stock logo

Neptune Wellness Solutions NASDAQ:NEPT

Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.

Norvista Capital CVE:NVV

C$0.08 -0.01 (-6.25%)
As of 01/12/2022

Norvista Capital Corporation operates as a resource investment company and merchant bank in the United States and Canada. It invests in a portfolio of companies that are involved in the exploration of base and precious metals, such as copper, zinc, silver, gold, and lead, as well as oil and gas located in Chile, Manitoba, Yukon, Mexico, and Nevada; and oil and gas in Israel, the United States, Brazil, and Canada. The company was founded in 2014 and is headquartered in Toronto, Canada.